Smith & Nephew plc (SN.L)

Smith & Nephew plc (SN.L) Trading on MT5 at XM

At XM we offer Smith & Nephew plc (SN.L) stocks as cash CFDs. Our cash CFDs stocks are undated transactions that aim to replicate the cash price of the underlying stock, and so they are adjusted for any relevant corporate actions.

Open a Demo Account
Open an Account

Risk warning: FX and CFD trading involves a high risk of loss.

About Smith & Nephew plc (SN.L) Trading

Smith & Nephew plc is a British multinational company that manufactures medical equipment sold in over 120 countries. Founded in 1856 and based in London and Hull, United Kingdom, the company products are related to wound management arthroscopy, trauma and clinical therapy, as well as orthopedic reconstruction. The company is a FTSE 100 index component, and its stock is traded on the London Stock Exchange.

Trading Conditions

Margin requirement 10 %
Spreads as low as 0.04
Symbols Smith & Nephew
Description Smith & Nephew PLC
Min. Price Fluctuation 0.01000
Value of Minimum Price Fluctuation GBP 0.1
Value of 1 lot 10 Shares
Min/Max Trade Size 1/268
Swap Value in Margin Currency Long -3.47 %
Swap Value in Margin Currency Short -2.53 %
Limit and Stop Levels** 0.05
Total Volume Limit (per client)*** 2678
Trading time (server time) 10:10-14:00,14:03-18:25 (GMT +2)
** Min. level for placing pending orders at a current market price.

*** Note that the maximum trading volume for Smith & Nephew per client is 2678 lots. This limit will be reviewed on a daily basis and updated according to the value of the instrument.

How to Start Trading Smith & Nephew plc (SN.L)?

Step 1

Open an XM Real Account


Step 2

Download and login to the MT5 platform


Step 3

Double-click on Smith & Nephew plc (SN.L) from the “Market Watch” to open an order for this instrument.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.